No Data
H.C. Wainwright Maintains Repligen(RGEN.US) With Buy Rating, Maintains Target Price $180
Repligen Price Target Maintained With a $180.00/Share by HC Wainwright & Co.
Repligen Corp. (RGEN) Slid On Uncertainty Related To U.S. Federal Government Spending On Healthcare
Jim Cramer on Repligen Corporation (RGEN): 'I'm Not Quite Ready to Stick My Neck Out on This One'
A Quick Look at Today's Ratings for Repligen(RGEN.US), With a Forecast Between $189 to $207
Repligen's Strong Market Position and Growth Potential Justify Buy Rating Amid Minimal Tariff Exposure